Effectiveness of the Smoke Free App for Smoking Cessation -- Results of RAUCHFREI, a Randomised, Double-blind, Controlled, Two-arm, Parallel, Nationwide, Decentralised, Fully Remote Clinical Trial in Germany

The RAUCHFREI trial, a large-scale, randomized, double-blind, controlled study conducted in Germany, demonstrates that the Smoke Free mobile app significantly increases smoking cessation rates among moderately dependent smokers compared to an informational app when used alongside brief healthcare professional advice.

The Gist

Imagine you are trying to climb a very steep, foggy mountain called "Quitting Smoking." For years, many people have tried to climb it alone, using only a map they found in a library (willpower) or a basic compass (brief advice from a doctor). But the fog is thick, and many slip back down.

This paper is about a new tool tested to help people reach the summit: the Smoke Free App.

Here is the story of how they tested it, told simply.

The Big Experiment: A Race with Two Teams

The researchers set up a massive, nationwide race in Germany. They didn't just ask people to download an app; they created a rigorous scientific "game" to see if the app actually works better than just reading a pamphlet.

• The Players: They recruited 1,466 adult smokers who were moderately dependent on cigarettes. Think of them as hikers who know the mountain is tough but are determined to climb it.
• The Setup: Everyone got a little pep talk from a medical professional first (the "brief advice"). Then, they were randomly split into two teams:
  1. The Super-Team (Intervention Group): They got the full Smoke Free App. This wasn't just a digital diary. It was like a high-tech hiking guide with interactive maps, gamified challenges (earning badges for milestones), and a virtual coach that cheered them on when they felt like quitting.
  2. The Text-Team (Control Group): They got a "dummy" app. It looked exactly the same on the phone screen, but when you opened it, it was just a static list of text facts—like a digital version of a paper brochure. It had no games, no coach, and no interactive features.

Why do this? To make sure that if the Super-Team won, it wasn't just because they liked playing with their phones. It had to be because the tools inside the app actually helped them quit.

The Rules of the Game

• Blindfolded: Neither the participants nor the researchers knew who was on which team until the end. This prevents bias (like hoping the app works so you think it works).
• The Finish Line: The main goal was to see who could stay off combustible cigarettes for 7 days straight, 6 months after starting the race.
• The Proof: To make sure people weren't just lying about quitting, about 60% of the people who said they quit had to spit into a test tube (a saliva test) to prove they had no nicotine in their system.

The Results: The App Wins Big

After 6 months, the results were clear:

• The Super-Team: About 39% of them successfully quit smoking.
• The Text-Team: Only about 24% of them quit.

The Analogy: Imagine two groups of people trying to learn a new language. One group uses an interactive app with games, speaking practice, and daily rewards. The other group just reads a dictionary. The app group learned the language at nearly double the rate of the dictionary group.

The study calculated that for every 7 people who used the Smoke Free app, one extra person quit smoking compared to if they had just used the text-only version. In the medical world, this is considered a huge success.

Was it Safe?

Yes. The researchers checked for any "side effects" or serious bad events. They found 84 serious health events across both groups (like a broken leg or a heart issue), but none were caused by the app. The app didn't hurt anyone; it just helped.

Why This Matters

1. It's Scalable: You can't hire a personal coach for every smoker in the world. But you can give an app to millions of people instantly. This study proves that a digital coach can be just as effective as a human one for many people.
2. It Works for Tough Cases: The study included people who were quite addicted (not just casual smokers). Even for them, the app doubled their chances of success.
3. The "Active Control" Trick: By giving the control group a "fake" app that looked real, the researchers proved that the interactive features (the games, the tracking, the coaching) were the secret sauce, not just the fact that they were using a phone.

The Bottom Line

Think of the Smoke Free app as a digital Swiss Army Knife for quitting smoking. While willpower is the engine, this app provides the gears, the map, and the fuel.

The study concludes that when a doctor gives a smoker a quick piece of advice and then hands them this app, it significantly boosts their chances of reaching the summit of a smoke-free life. It's a win for technology, a win for health, and a win for anyone trying to put down the cigarette.

Technical Summary

1. Problem Statement

Despite the availability of evidence-based smoking cessation support, uptake remains low globally, particularly in Germany where only a small minority of smokers utilize such methods during quit attempts. While mobile health (mHealth) applications offer a scalable, cost-effective solution, their efficacy is often uncertain due to:

• Lack of rigorous evidence: Most evaluations suffer from low follow-up rates or lack randomization.
• Inadequate controls: Many studies compare apps to "treatment as usual" rather than controlling for the non-specific effects of app usage (e.g., attention, novelty, interface usability).
• Uncertainty regarding pharmacotherapy: It is unclear if apps are effective as standalone interventions without concurrent pharmacotherapy.
• Regulatory requirements: In Germany, Digital Health Applications (DiGAs) must demonstrate clinical efficacy in Randomized Controlled Trials (RCTs) to be reimbursed by health insurance, yet large-scale, double-blind trials for smoking cessation apps were lacking.

2. Methodology

The study, known as RAUCHFREI, was a prospective, randomized, double-blind, controlled, two-arm, parallel, nationwide, decentralized, and fully remote clinical trial conducted in Germany.

• Study Design:

  • Type: Double-blind RCT (participants and study personnel were blinded to allocation).
  • Setting: Fully remote; recruitment via digital channels (ads, app stores) and video consultations.
  • Duration: 6-month follow-up.
  • Registration: German Clinical Trials Register (DRKS00031140).

• Participants:

  • Sample Size: 1,466 adult cigarette smokers (aged 18–65) with at least moderate dependence (Fagerström Test for Cigarette Dependence [FTCD] ≥ 3).
  • Recruitment Period: August 2023 to February 2024.
  • Inclusion: Motivated to quit, compatible smartphone, German residency, B2 German language skills.
  • Exclusion: Untreated substance use disorders, acute severe psychiatric disorders, recent use of Smoke Free, or living with another trial participant.

• Interventions:

  • Common Baseline: All participants received the "ABC" brief intervention (Ask, Brief advice, Cessation support) from medically trained staff via video consultation. No pharmacotherapy was provided as part of the trial protocol.
  • Intervention Group (IG, n=720): Received the full Smoke Free app for 6 months. Features included interactive behavior-change missions, progress tracking, personalized motivational support, and gamification.
  • Control Group (CG, n=746): Received a text-only informational app for 6 months. This "active control" was visually identical to the IG app on the home screen but contained only static cessation information (modeled on GP brochures) with no interactive or gamified elements.

• Outcomes:

  • Primary Outcome: Self-reported 7-day point-prevalence abstinence (PPA) from combustible tobacco at 6 months (missing data treated as smoking).
  • Secondary Outcomes:
    • Biochemically validated abstinence (saliva cotinine test, cut-off 20 ng/mL) at 6 months.
    • Repeated 7-day PPA (continuous abstinence across all follow-ups).
    • Continuous abstinence allowing a maximum of 5 cigarettes (slips).
    • Abstinence from all tobacco products and ENDS (nicotine abstinence).
  • Safety: Monitoring of Serious Adverse Events (SAEs).

• Statistical Analysis:

  • Principle: Intention-to-Treat (ITT).
  • Method: Logistic regression to calculate Odds Ratios (OR) with 95% Confidence Intervals (CI).
  • Adjustments: Exploratory models adjusted for sex, age, SES, smoking history, and baseline motivation/confidence.
  • Sensitivity Analyses: Multiple imputation, subgroup analysis by stratification variables, and alternative imputation for active withdrawals.

3. Key Contributions

• Methodological Rigor: This is one of the largest and most rigorous DiGA trials to date, featuring a double-blind design and a high retention rate (>84%), addressing the common flaw of low follow-up in digital health studies.
• Active Control Design: By using a text-only app that mimicked the interface of the intervention app, the study successfully isolated the specific efficacy of the behavior-change techniques from non-specific effects (e.g., attention, novelty, and app usability). This sets a new standard for control groups in digital intervention research.
• Real-World Applicability: The trial was conducted entirely remotely and decentralized, demonstrating the feasibility of large-scale digital clinical trials within the German healthcare system.
• Focus on Dependent Smokers: The study specifically targeted smokers with moderate-to-high dependence (FTCD ≥ 3), a group often excluded from app-only studies due to the perceived need for pharmacotherapy.

4. Results

• Primary Outcome (Self-Reported Abstinence):

  • The Intervention Group (IG) achieved significantly higher abstinence rates than the Control Group (CG).
  • IG: 283/720 (39.3%) vs. CG: 182/746 (24.4%).
  • Odds Ratio (OR): 2.01 (95% CI 1.60–2.50, p < 0.0001).
  • Number Needed to Treat (NNT): 6.7 (5.1 to 9.8).
  • The effect remained significant after adjusting for covariates (OR = 2.1).

• Secondary Outcomes:

  • Biochemical Validation: Among participants who provided saliva samples, the IG showed significantly higher confirmed abstinence (14.6% vs. 8.8%; OR 1.8, p < 0.0001).
  • Consistency: The IG outperformed the CG across all definitions of abstinence (tobacco, nicotine, repeated PPA, and continuous abstinence), with ORs ranging from 1.8 to 2.3.
  • Follow-up Rates: No significant difference in attrition between groups (IG: 16.5% loss; CG: 15.3% loss; p=0.52).

• Safety:

  • 84 Serious Adverse Events (SAEs) were reported by 75 participants (IG: 4.3%; CG: 5.9%).
  • Crucially, none of the SAEs were classified as treatment-related.

• User Engagement & Satisfaction:

  • IG participants reported higher satisfaction (Mean 3.7 vs. 2.4) and higher Net Promoter Scores (30.3% promoters vs. 7.6%).
  • Higher app engagement (more openings) correlated with successful abstinence.

5. Significance

• Clinical Efficacy: The study provides robust evidence that the Smoke Free app is an effective standalone intervention for smoking cessation, doubling the odds of quitting compared to informational support alone.
• Health Policy Impact: The results support the inclusion of the Smoke Free app in the German DiGA list, allowing it to be prescribed by doctors and reimbursed by health insurance, thereby scaling access to evidence-based cessation tools.
• Scalability: The success of a fully remote, decentralized trial demonstrates that high-quality RCTs can be conducted efficiently at a national scale without physical infrastructure.
• Future Research: The study validates the use of "active controls" (text-only apps) in digital health research to prevent overestimation of treatment effects due to placebo or novelty effects. It also highlights the potential for digital interventions to reach highly dependent smokers who may not access traditional face-to-face services.

Conclusion: The RAUCHFREI trial confirms that the Smoke Free app, when used as an adjunct to brief professional advice, is a highly effective, safe, and scalable tool for smoking cessation, particularly for moderately to severely dependent smokers.